Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload

被引:0
作者
Jiong-Wei Wang
Magda S. C. Fontes
Xiaoyuan Wang
Suet Yen Chong
Elise L. Kessler
Ya-Nan Zhang
Judith J. de Haan
Fatih Arslan
Saskia C. A. de Jager
Leo Timmers
Toon A. B. van Veen
Carolyn S. P. Lam
Dominique P. V. de Kleijn
机构
[1] Yong Loo Lin School of Medicine,Department of Surgery
[2] National University of Singapore,Cardiovascular Research Institute (CVRI)
[3] National University Heart Centre Singapore (NUHCS) and National University Health System (NUHS),Department of Medical Physiology
[4] Division of Heart & Lungs,Laboratory of Experimental Cardiology
[5] University Medical Center Utrecht,Department of Cardiology
[6] Utrecht,Laboratory of Translational Immunology
[7] Department of Cardiology,National Heart Centre Singapore
[8] Heart Lung Center Leiden,Cardiology
[9] Leiden University Medical Center,Department of Vascular Surgery
[10] University Medical Center Utrecht,undefined
[11] University Medical Center Utrecht,undefined
[12] Duke-NUS Graduate Medical School,undefined
[13] University Medical Center,undefined
[14] University Medical Center Utrecht,undefined
[15] Netherlands Heart Institute,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
An involement of Toll-like receptor 2 (TLR2) has been established in cardiac dysfunction after acute myocardial infarction; however, its role in chronic pressure overload is unclear. We sought to evaluate the role of TLR2 in cardiac hypertrophy, fibrosis and dysfunction in sustained pressure overload. We induced pressure overload via transverse aortic constriction (TAC) in TLR2−/− and wild type (WT) mice, and followed temporal changes over 8 weeks. Despite similar increases in heart weight, left ventricular (LV) ejection fraction (EF) and diastolic function (mitral E/A ratio) were preserved in TLR2−/− mice but impaired in WT mice following TAC. TAC produced less LV fibrosis in TLR2−/− mice associated with lower mRNA levels of collagen genes (Col1a1 and Col3a1) and lower protein level of TGFbeta1, compared to WT mice. Following TAC, the influx of macrophages and CD3 T cells into LV was similar between TLR2−/− and WT mice, whereas levels of cyto/chemokines were lower in the heart and plasma in TLR2−/− mice. TLR2−/− bone marrow-derived cells protected against LVEF decline and fibrosis following TAC. Our findings show that leukocytic TLR2 deficiency protects against LV dysfunction and fibrosis probably via a reduction in inflammatory signaling in sustained pressure overload.
引用
收藏
相关论文
共 39 条
[1]  
Kannel WB(1972)Role of blood pressure in the development of congestive heart failure. The Framingham study N Engl J Med 287 781-787
[2]  
Castelli WP(2013)2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 e147-239
[3]  
McNamara PM(2016)Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation Eur J Heart Fail 18 588-598
[4]  
McKee PA(2014)Danger signals in cardiovascular disease Mediators Inflamm 2014 301-305
[5]  
Feinleib M(2002)The danger model: a renewed sense of self Science 296 279-287
[6]  
Yancy CW(2012)Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs Circ Cardiovasc Interv 5 80-90
[7]  
Ter Maaten JM(2010)Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody Circulation 121 383-392
[8]  
Frantz S(2015)Knockout of Toll-Like Receptors 2 and 4 Prevents Renal Ischemia-Reperfusion-Induced Cardiac Hypertrophy in Mice PLoS One 10 265-272
[9]  
Monaco C(2012)Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice PLoS One 7 161-170
[10]  
Arslan F(2014)Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation Cardiovasc Res 101 2213-2224